TScan Therapeutics Inc.
Organization details
- Legal name
- TScan Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TCRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001783328
- EIN
- 82-5282075
Board of directors
-
Barbara Klencke · DirectorSince 2023
-
David P. Southwell · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Gabriela Gruia · DirectorSince 2023
-
Garry A. Nicholson · DirectorSince 2024
-
Gavin MacBeath · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Katina Dorton · DirectorSince 2023
-
Keith Woods · DirectorSince 2023
-
Timothy J. Barberich · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.4%
Board connections
8 of this board's directors also sit on 23 other boards. 23 are in the same sector.
-
Neurogene Inc. Same sectorvia Felix Baker, Julian Baker and Keith Woods
-
Prelude Therapeutics Incorporated Same sectorvia Felix Baker, Julian Baker and Katina Dorton
-
ACADIA Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
BeOne Medicines Ltd. Same sectorvia Felix Baker and Julian Baker
-
Bicycle Therapeutics plc Same sectorvia Felix Baker and Julian Baker
-
DBV Technologies S.A. Same sectorvia Felix Baker and Julian Baker
-
Denali Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Immunocore Holdings plc Same sectorvia Felix Baker and Julian Baker
-
Incyte Corp. Same sectorvia Felix Baker and Julian Baker
-
Kiniksa Pharmaceuticals International plc Same sectorvia Felix Baker and Julian Baker
-
Kodiak Sciences Inc Same sectorvia Felix Baker and Julian Baker
-
Kymera Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Madrigal Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
Replimune Group Inc. Same sectorvia Felix Baker and Julian Baker
-
Rocket Pharmaceuticals Inc. Same sectorvia David P. Southwell and Keith Woods
-
vTv Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
ALX Oncology Holdings Inc. Same sectorvia Barbara Klencke
-
Aprea Therapeutics Inc. Same sectorvia Gabriela Gruia
-
Fulcrum Therapeutics Inc. Same sectorvia Katina Dorton
-
NextCure Inc. Same sectorvia Garry A. Nicholson
-
PTC Therapeutics Inc. Same sectorvia David P. Southwell
-
X4 Pharmaceuticals Inc. Same sectorvia Keith Woods
-
Xencor Inc. Same sectorvia Barbara Klencke
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $145,621
- 3 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Gavin MacBeath Director, Officer (Chief Executive Officer) | Grant or award | +1,000,000 | — | — |
| Oct 1, 2026 | ZDRAVESKI ZORAN Officer (See Remarks) | Grant or award | +300,000 | — | — |
| Dec 23, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +6,232 | $0.90 | $5,609 |
| Dec 22, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +75,500 | $0.90 | $67,950 |
| Dec 19, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +80,069 | $0.90 | $72,062 |
| May 20, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +1,200,000 | $1.20 | $1,440,000 |
| May 19, 2025 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +1,388,794 | $1.20 | $1,666,553 |
| Dec 13, 2024 | Nichols Weston 10% owner | Open-market purchase | +100,000 | $2.90 | $290,000 |
| Dec 12, 2024 | Nichols Weston 10% owner | Open-market purchase | +31,800 | $3.01 | $95,718 |
| Nov 15, 2024 | Nichols Weston 10% owner | Open-market purchase | +947 | $4.34 | $4,110 |
| Sep 23, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.29 | $26,450 |
| Aug 26, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.53 | $27,650 |
| Aug 23, 2024 | Barbara Klencke Director | Open-market purchase | +5,000 | $5.69 | $28,450 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +54,895 | $4.85 | $266,241 |
| Aug 23, 2024 | ZDRAVESKI ZORAN Officer (See Remarks) | Option exercise | +25,000 | $3.27 | $81,750 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about TScan Therapeutics Inc.
Who is the CEO of TScan Therapeutics Inc.?
David P. Southwell is TScan Therapeutics Inc.'s Chief Executive Officer.
How many directors are on TScan Therapeutics Inc.'s board?
TScan Therapeutics Inc.'s board has 10 directors: Barbara Klencke, David P. Southwell, Felix Baker, Gabriela Gruia, Garry A. Nicholson, Gavin MacBeath, Julian Baker, Katina Dorton, Keith Woods and Timothy J. Barberich.
Are TScan Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, TScan Therapeutics Inc. insiders bought $145,621 of shares in 3 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="tscan-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.